Insufficient scRNA-seq data for expression of MYOG at single-cell level.
Insufficient scRNA-seq data for expression of MYOG at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
muscle | 100% | 4117.41 | 803 / 803 | 0% | 0 | 0 / 0 |
brain | 66% | 11.38 | 1734 / 2642 | 4% | 0.08 | 30 / 705 |
kidney | 34% | 2.70 | 30 / 89 | 1% | 0.05 | 5 / 901 |
prostate | 16% | 125.78 | 38 / 245 | 9% | 1.36 | 45 / 502 |
breast | 8% | 4.54 | 35 / 459 | 5% | 0.22 | 51 / 1118 |
heart | 12% | 0.97 | 100 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 11% | 2.29 | 5 / 45 |
uterus | 2% | 0.16 | 3 / 170 | 8% | 56.95 | 37 / 459 |
thymus | 6% | 2.22 | 36 / 653 | 2% | 0.15 | 10 / 605 |
lung | 6% | 0.73 | 37 / 578 | 1% | 0.03 | 8 / 1155 |
peripheral blood | 7% | 2.03 | 65 / 929 | 0% | 0 | 0 / 0 |
ovary | 2% | 0.12 | 3 / 180 | 5% | 0.56 | 20 / 430 |
adipose | 6% | 1.22 | 74 / 1204 | 0% | 0 | 0 / 0 |
skin | 5% | 6.67 | 84 / 1809 | 1% | 0.06 | 6 / 472 |
esophagus | 4% | 6.72 | 65 / 1445 | 1% | 0.01 | 1 / 183 |
blood vessel | 5% | 3.19 | 61 / 1335 | 0% | 0 | 0 / 0 |
intestine | 4% | 0.41 | 39 / 966 | 0% | 0.00 | 2 / 527 |
spleen | 4% | 0.30 | 9 / 241 | 0% | 0 | 0 / 0 |
stomach | 2% | 0.20 | 7 / 359 | 1% | 0.02 | 4 / 286 |
liver | 3% | 0.29 | 6 / 226 | 0% | 0 | 0 / 406 |
pancreas | 2% | 0.26 | 6 / 328 | 0% | 0 | 0 / 178 |
adrenal gland | 1% | 0.09 | 3 / 258 | 0% | 0 | 0 / 230 |
bladder | 0% | 0 | 0 / 21 | 0% | 0.01 | 1 / 504 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0071285 | Biological process | cellular response to lithium ion |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0007519 | Biological process | skeletal muscle tissue development |
GO_0014891 | Biological process | striated muscle atrophy |
GO_0048741 | Biological process | skeletal muscle fiber development |
GO_0014894 | Biological process | response to denervation involved in regulation of muscle adaptation |
GO_0071392 | Biological process | cellular response to estradiol stimulus |
GO_0045663 | Biological process | positive regulation of myoblast differentiation |
GO_0014737 | Biological process | positive regulation of muscle atrophy |
GO_0014878 | Biological process | response to electrical stimulus involved in regulation of muscle adaptation |
GO_0071363 | Biological process | cellular response to growth factor stimulus |
GO_0042693 | Biological process | muscle cell fate commitment |
GO_0010831 | Biological process | positive regulation of myotube differentiation |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0014842 | Biological process | regulation of skeletal muscle satellite cell proliferation |
GO_1901739 | Biological process | regulation of myoblast fusion |
GO_0001503 | Biological process | ossification |
GO_0035914 | Biological process | skeletal muscle cell differentiation |
GO_0014873 | Biological process | response to muscle activity involved in regulation of muscle adaptation |
GO_0048743 | Biological process | positive regulation of skeletal muscle fiber development |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0032993 | Cellular component | protein-DNA complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005667 | Cellular component | transcription regulator complex |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0043565 | Molecular function | sequence-specific DNA binding |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0001216 | Molecular function | DNA-binding transcription activator activity |
GO_0031490 | Molecular function | chromatin DNA binding |
GO_0070888 | Molecular function | E-box binding |
GO_0046983 | Molecular function | protein dimerization activity |
GO_0005515 | Molecular function | protein binding |
Gene name | MYOG |
Protein name | Myogenin (Class C basic helix-loop-helix protein 3) (bHLHc3) (Myogenic factor 4) (Myf-4) Alternative protein MYOG |
Synonyms | MYF4 BHLHC3 |
Description | FUNCTION: Acts as a transcriptional activator that promotes transcription of muscle-specific target genes and plays a role in muscle differentiation, cell cycle exit and muscle atrophy. Essential for the development of functional embryonic skeletal fiber muscle differentiation. However is dispensable for postnatal skeletal muscle growth; phosphorylation by CAMK2G inhibits its transcriptional activity in respons to muscle activity. Required for the recruitment of the FACT complex to muscle-specific promoter regions, thus promoting gene expression initiation. During terminal myoblast differentiation, plays a role as a strong activator of transcription at loci with an open chromatin structure previously initiated by MYOD1. Together with MYF5 and MYOD1, co-occupies muscle-specific gene promoter core regions during myogenesis. Cooperates also with myocyte-specific enhancer factor MEF2D and BRG1-dependent recruitment of SWI/SNF chromatin-remodeling enzymes to alter chromatin structure at myogenic late gene promoters. Facilitates cell cycle exit during terminal muscle differentiation through the up-regulation of miR-20a expression, which in turn represses genes involved in cell cycle progression. Binds to the E-box containing (E1) promoter region of the miR-20a gene. Plays also a role in preventing reversal of muscle cell differentiation. Contributes to the atrophy-related gene expression in adult denervated muscles. Induces fibroblasts to differentiate into myoblasts (By similarity). . |
Accessions | ENST00000241651.5 L8E8X4 P15173 |